ES2062392T3 - Medicamentos que comprenden salmeterol y fluticasona. - Google Patents

Medicamentos que comprenden salmeterol y fluticasona.

Info

Publication number
ES2062392T3
ES2062392T3 ES90309846T ES90309846T ES2062392T3 ES 2062392 T3 ES2062392 T3 ES 2062392T3 ES 90309846 T ES90309846 T ES 90309846T ES 90309846 T ES90309846 T ES 90309846T ES 2062392 T3 ES2062392 T3 ES 2062392T3
Authority
ES
Spain
Prior art keywords
fluticasone
medications including
salmeterol
including salmeterol
sequential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90309846T
Other languages
English (en)
Spanish (es)
Inventor
James Barry Douglas Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2062392(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2062392T3 publication Critical patent/ES2062392T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
ES90309846T 1989-09-08 1990-09-07 Medicamentos que comprenden salmeterol y fluticasona. Expired - Lifetime ES2062392T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
ES2062392T3 true ES2062392T3 (es) 1994-12-16

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90309846T Expired - Lifetime ES2062392T3 (es) 1989-09-08 1990-09-07 Medicamentos que comprenden salmeterol y fluticasona.

Country Status (20)

Country Link
EP (1) EP0416951B1 (en])
JP (1) JP3042867B2 (en])
AT (1) ATE99941T1 (en])
BE (1) BE1003053A3 (en])
CA (1) CA2024916C (en])
CH (1) CH680983C9 (en])
DE (2) DE19975040I2 (en])
DK (1) DK0416951T3 (en])
ES (1) ES2062392T3 (en])
FR (1) FR2651677B1 (en])
HK (1) HK18695A (en])
HU (1) HU211272A9 (en])
IE (1) IE65535B1 (en])
IL (1) IL95590A (en])
IT (1) IT1241996B (en])
LU (1) LU90392I2 (en])
NL (1) NL990012I2 (en])
NZ (1) NZ235221A (en])
PH (1) PH27594A (en])
SG (1) SG166294G (en])

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE213946T1 (de) * 1991-12-18 2002-03-15 Formoterol und budesonide enthaltende zusammensetzung
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
AU756852B2 (en) 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
WO2001019342A2 (en) 1999-09-11 2001-03-22 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
AU2001276497B2 (en) 2000-08-05 2005-04-07 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
CN101701006B (zh) 2001-09-14 2014-03-05 葛兰素集团有限公司 治疗呼吸疾病的苯乙醇胺衍生物
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
ATE396716T1 (de) † 2002-02-04 2008-06-15 Glaxo Group Ltd Zubereitung zur inhalation enthaltend ein glucocorticoid und einen beta 2-adrenorezeptor agonisten
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
ATE405275T1 (de) 2002-12-12 2008-09-15 Nycomed Gmbh Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
WO2005087192A2 (en) * 2004-03-12 2005-09-22 Cipla Limited Salmeterol inhalation formulations
DK1616592T3 (da) 2004-07-16 2011-01-10 Almirall Sa Inhalator til administration af lægemidler i pulverform og en pulverpatron til anvendelse sammen med denne inhalator
AU2007338305B2 (en) 2006-12-22 2013-05-09 Astrazeneca Ab Inhalation device for drugs in powder form
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US8808713B2 (en) 2009-05-29 2014-08-19 Pearl Thereapeutics, Inc. Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
MY178819A (en) 2013-03-15 2020-10-20 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
WO2014177519A1 (en) * 2013-04-29 2014-11-06 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
EP0416951A1 (en) 1991-03-13
ATE99941T1 (de) 1994-01-15
IT9048260A1 (it) 1992-03-07
JP3042867B2 (ja) 2000-05-22
IE65535B1 (en) 1995-11-01
HK18695A (en) 1995-02-17
NZ235221A (en) 1992-11-25
CA2024916C (en) 2002-07-09
IE903256A1 (en) 1991-03-13
NL990012I2 (nl) 1999-09-01
CH680983C9 (en]) 2008-08-15
FR2651677B1 (fr) 1993-08-06
DE69005951D1 (de) 1994-02-24
DE69005951T2 (de) 1994-05-26
FR2651677A1 (fr) 1991-03-15
DK0416951T3 (da) 1994-02-14
CH680983A5 (en]) 1992-12-31
LU90392I2 (fr) 1999-06-28
NL990012I1 (nl) 1999-07-01
JPH03167120A (ja) 1991-07-19
BE1003053A3 (fr) 1991-11-05
IL95590A (en) 1996-06-18
DE19975040I2 (de) 2006-07-13
CA2024916A1 (en) 1991-03-09
HU211272A9 (en) 1995-11-28
IT9048260A0 (it) 1990-09-07
EP0416951B1 (en) 1994-01-12
CH680983C1 (en]) 2008-06-25
IL95590A0 (en) 1991-09-16
IT1241996B (it) 1994-02-02
PH27594A (en) 1993-08-31
SG166294G (en) 1995-06-16

Similar Documents

Publication Publication Date Title
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
DK0416950T3 (da) Medikamenter
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
ATE173627T1 (de) Medizinische zusammensetzung
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
ES2059312T3 (es) Medicamento que puede administrarse por via nasal, procedimiento para su preparacion y su aplicacion.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ES2059130T3 (es) Composiciones farmaceuticas que contienen ipriflavona, procedimiento para su preparacion y uso terapeutico relacionado.
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
IT8448710A1 (it) Riduzione degli effetti tossici causati da farmaci antrachinonici
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
MY111155A (en) Medicaments
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.
RU93003454A (ru) Лекарственный препарат
IT1271354B (it) Preparazione di una forma farmaceutica atta a combattere l'iperinsulinismo contenente n-acetil cisteine e loro analoghi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 416951

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: XINAFOATO DE SALMETEROL Y PROPIONATO DE FLUTICASONA (SERITIDE)

Spc suppl protection certif: C9900031

Filing date: 19990921

SPCG Supplementary protection certificate granted

Free format text: XINAFOATO DE SALMETEROL Y PROPIONATO DE FLUTICASONA (SERETIDE)

Spc suppl protection certif: C9900031

Filing date: 19990921

Expiry date: 20130907

Effective date: 20021119